- Disulfiram markedly ameliorated adenine-induced kidney injury, reducing inflammatory cell infiltration and inflammasome and pyroptosis-related markers.
- RNA sequencing showed disulfiram restored disrupted fatty acid metabolism, indicating modulation of renal immunometabolic pathways.
- Disulfiram alleviated DNA damage, cellular senescence, and fibrosis; gasdermin D activation correlated with CKD severity in human biopsy samples.
FASEB J. 2026 Sep 30;40(18):e72299. doi: 10.1096/fj.202601271RR.
ABSTRACT
Chronic kidney disease (CKD) is partly driven by excessive innate immune activation, which contributes to progressive renal injury and fibrosis. Disulfiram (DSF), an approved treatment for alcohol dependence, has recently emerged as an inhibitor of innate immune responses such as pyroptosis. In this study, we investigated whether DSF attenuates kidney injury in adenine-induced nephropathy and explored the underlying mechanisms. DSF treatment markedly ameliorated kidney injury in adenine-induced nephropathy, accompanied by suppression of inflammatory cell infiltration and inflammasome- and pyroptosis-related markers. RNA sequencing revealed restoration of disrupted fatty acid metabolism in the kidneys following DSF treatment. Furthermore, DSF alleviated DNA damage, cellular senescence, and fibrosis. Importantly, activation of gasdermin D, a central executor of pyroptosis, was closely associated with disease severity in human CKD biopsy samples, supporting the clinical relevance of this pathway. Collectively, these findings suggest a potential role for DSF in modulating inflammatory and immunometabolic pathways in CKD.
PMID:42750476 | DOI:10.1096/fj.202601271RR
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
